IP Library Granted Patent US 8,735,342
Granted Patent B2
US 8,735,342 · App. 13/575,289 · Granted May 27, 2014

Method for treating brain cancer using a novel tumor suppressor gene and secreted factor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,735,342
App. No.
13/575,289
Granted
May 27, 2014
Kind
B2
Abstract

The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers.

Claims (9)

1. A method for treating a brain cancer that is glioblastoma or astrocytoma, comprising administering via intracerebroventricular infusion to the brain of a subject in need of treatment of glioblastoma or astrocytoma an effective amount of Hematopoietic Signal peptide-containing Secreted 1 (HSS1) comprising SEQ ID NO: 6.

2. The method of claim 1 , wherein the brain cancer is a primary brain cancer that is glioblastoma or astrocytoma.

3. The method of claim 1 , wherein the HSS1 is delivered before or after radiation therapy.

4. The method of claim 1 , wherein the HSS1 is delivered before or after brain surgery to remove all or part of the cancerous tissue.

5. The method of claim 1 , wherein the HSS1 is delivered before or after chemotherapy.

6. The method of claim 1 , wherein the subject treated with the HSS1 has increased survival following treatment.

7. The method of claim 1 , wherein treatment with the HSS1 results in a reduction in mass of the glioblastoma or astrocytoma.

8. The method of claim 1 , wherein an effective and safe dose of the HSS1 is administered to the subject in need of treatment of glioblastoma or astrocytoma.

9. A method for treating a brain cancer that is glioblastoma or astrocytoma, comprising administering via intracerebroventricular infusion to the brain of a subject in need of treatment of glioblastoma or astrocytoma an effective amount of a peptide having at least about 95% homology to Hematopoietic Signal peptide-containing Secreted 1 (HSS1) comprising SEQ ID NO: 6.

Assignments (8)
RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME NO. 67396/0532 Recorded Oct 14, 2025
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT
To: KARYOPHARM THERAPEUTICS INC.
Reel/Frame 073111/0142 →
PATENT SECURITY AGREEMENT Recorded Oct 10, 2025
From: KARYOPHARM THERAPEUTICS INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL TRUSTEE
Reel/Frame 073058/0504 →
SECOND LIEN PATENT SECURITY AGREEMENT Recorded May 13, 2024
From: KARYOPHARM THERAPEUTICS INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 067396/0532 →
SECURITY INTEREST Recorded May 8, 2024
From: KARYOPHARM THERAPEUTICS INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 067345/0255 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2023
From: NEUMEDICINES INC.
To: KARYOPHARM THERAPEUTICS INC.
Reel/Frame 065879/0436 →
NOTICE OF TERMINATION AND RELEASE OF PATENT LIENS AND SECURITY INTERESTS Recorded Jul 28, 2021
From: NEUMEDICINES INC.
To: KARYOPHARM THERAPEUTICS INC.
Reel/Frame 057012/0881 →
SECURITY INTEREST Recorded Jun 16, 2020
From: NEUMEDICINES INC.
To: FRIEDMAN, ELLIOT
Reel/Frame 052956/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2012
From: BASILE, LENA A.; GALLAHER, TIMOTHY KIRK
To: NEUMEDICINES, INC.
Reel/Frame 028950/0324 →